XML 60 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SHAREHOLDERS' EQUITY (Share Option Plans) (Narrative) (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Oct. 10, 2018
USD ($)
$ / shares
Jun. 14, 2018
USD ($)
$ / shares
shares
May 25, 2018
USD ($)
Dec. 31, 2019
USD ($)
$ / shares
shares
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2019
₪ / shares
Dec. 31, 2018
₪ / shares
May 25, 2018
₪ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Weighted average fair value of stock options granted | $ / shares       $ 1.67 $ 1.55 $ 1.66      
Unrecognized share-based compensation expense       $ 4,930          
Unrecognized compensation cost, recognition period       2 years 10 months 6 days          
Ordinary shares, par value | ₪ / shares             ₪ 0.01 ₪ 0.01  
Offering price per share | ₪ / shares             ₪ 0.01    
Ordinary shares, shares authorized | shares       200,000,000 100,000,000        
Equity investment       $ 12,000          
Deferred participation of BMS in R&D expenses       4,121          
Director [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Aggregate intrinsic value of exercised options       $ 979 $ 1,521 $ 351      
2000 and 2010 Share Option Plans [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Ordinary shares reserved for issuance | shares       10,395,152          
Ordinary shares available for issuance | shares       1,294,804          
Vesting period       4 years          
Award expiration period       10 years          
At The Market Offering Program [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Ordinary shares, par value | ₪ / shares                 ₪ 0.01
Proceeds from issuance of common stock     $ 25,000 $ 22,914          
Issuance of shares, net, shares | shares       7,245,268          
Issuance expenses       $ 781          
Agreement [Member] | Registered direct offering [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Offering price per share | $ / shares   $ 3.95              
Proceeds from issuance of common stock   $ 19,767              
Ordinary shares, shares authorized | shares   5,316,457              
Warrants purchase to ordinary shares | shares   4,253,165              
Exercise price of warrants | $ / shares   $ 4.74              
Expiration period of warrants   5 years              
Issuance expenses   $ 1,233              
Master Clinical Agreement [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Offering price per share | $ / shares $ 4.95                
Proceeds from issuance of common stock $ 2,424,243                
Equity investment $ 12,000                
Percentage of closing price 33.00%                
Collaborative Arrangements [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Proceeds from issuance of common stock       7,788          
Issuance expenses       $ 91